AU2005310239A1 - 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease - Google Patents

2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease Download PDF

Info

Publication number
AU2005310239A1
AU2005310239A1 AU2005310239A AU2005310239A AU2005310239A1 AU 2005310239 A1 AU2005310239 A1 AU 2005310239A1 AU 2005310239 A AU2005310239 A AU 2005310239A AU 2005310239 A AU2005310239 A AU 2005310239A AU 2005310239 A1 AU2005310239 A1 AU 2005310239A1
Authority
AU
Australia
Prior art keywords
group
alkyl
pct
original
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005310239A
Other languages
English (en)
Inventor
Craig A. Coburn
M. Katharine Holloway
Shawn J. Stachel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2005310239A1 publication Critical patent/AU2005310239A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2005310239A 2004-10-29 2005-10-25 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease Abandoned AU2005310239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62344104P 2004-10-29 2004-10-29
US60/623,441 2004-10-29
PCT/US2005/039932 WO2006060109A1 (en) 2004-10-29 2005-10-25 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2005310239A1 true AU2005310239A1 (en) 2006-06-08

Family

ID=36565355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005310239A Abandoned AU2005310239A1 (en) 2004-10-29 2005-10-25 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease

Country Status (7)

Country Link
US (1) US7932275B2 (https=)
EP (1) EP1807396B1 (https=)
JP (1) JP2008518969A (https=)
CN (1) CN101052618A (https=)
AU (1) AU2005310239A1 (https=)
CA (1) CA2585279A1 (https=)
WO (1) WO2006060109A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2006306542B2 (en) * 2005-10-21 2012-04-19 Merck Sharp & Dohme Corp. Potassium channel inhibitors
EP2402320A1 (en) 2006-03-31 2012-01-04 Novartis AG Anorectic agents
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
AU2009217518A1 (en) 2008-02-28 2009-09-03 Merck Sharp & Dohme Corp. 2-aminoimidazole beta-secretase inhibitors for the treatment of Alzheimer's disease
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP6903825B2 (ja) * 2017-12-19 2021-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング γ−セクレターゼのモジュレーターとしてのトリアゾロピリジン
CN111533684B (zh) * 2020-05-29 2021-10-29 四川大学 一种吡啶化合物烯基化的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JP4251868B2 (ja) * 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
US6951946B2 (en) * 2002-03-19 2005-10-04 Lexicon Pharmaceuticals, Inc. Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates
US7132568B2 (en) 2002-06-17 2006-11-07 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
WO2005005374A1 (en) 2003-06-16 2005-01-20 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EP1831170A4 (en) 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE

Also Published As

Publication number Publication date
US7932275B2 (en) 2011-04-26
WO2006060109B1 (en) 2006-08-10
EP1807396B1 (en) 2013-06-26
EP1807396A1 (en) 2007-07-18
CA2585279A1 (en) 2006-06-08
US20080161363A1 (en) 2008-07-03
WO2006060109A1 (en) 2006-06-08
CN101052618A (zh) 2007-10-10
JP2008518969A (ja) 2008-06-05
EP1807396A4 (en) 2009-09-09

Similar Documents

Publication Publication Date Title
AU2005310239A1 (en) 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
US5696137A (en) Azaheterocyclymethyl-chromans
TWI583685B (zh) Ｒｏｒｃ２的經甲基及三氟甲基取代之吡咯並吡啶調節劑及其使用方法
JP5780954B2 (ja) ヒスタミンｈ３受容体アンタゴニストとしてのアゼチジン類及びシクロブタン類
EP2262766A2 (en) Amide compounds, compositions and uses thereof
WO2005004803A2 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
JP2003212868A (ja) ５−ｈｔ４レセプターモジュレーターとしてのオキソ又はオキシピリジン
CA2570995A1 (en) Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
JP7381578B2 (ja) ヒストンデアセチラーゼの二環式阻害剤
JP5412430B2 (ja) ｍＧｌｕ５拮抗薬としての新規複素環系化合物
WO2019063748A1 (en) INHIBITORS OF ROR-GAMMA
CN110072859A (zh) 作为RORγ调节剂的化合物
EP2231558B1 (en) 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
KR20260005244A (ko) 치환된 티오펜 융합 유도체, 이를 포함하는 조성물, 및 의약품으로서의 이들의 용도
CN119768169A (zh) 取代的稠合二环化合物以及相关的治疗方法
JP2006511528A (ja) Ｎｒ２ｂレセプターアンタゴニストとしての２−ピリジル及び２−ピリミジルシクロアルキレンアミド化合物
US7816378B2 (en) Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
EA039459B1 (ru) Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа
WO2021020363A1 (ja) 複素環化合物
HK1197669A (en) Amide compounds, compositions and uses thereof
HK1198030B (en) Amide compounds, compositions and uses thereof
HK1174625A1 (en) Pyrrazolopyridine derivatives
TW200813031A (en) S1P receptor modulating compounds and use thereof
HK1174625B (en) Pyrrazolopyridine derivatives

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application